Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Column Group LLC

Q2 2023 · 13F-HR

Column Group LLCholdings as filed

Filed 2023-07-24 · accession 0000950123-23-006249

$257.7M
Reported value
7
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
76155X100RVMDRevolution Medicines Inc$68.9M26.8%2,577,220CommonSOLE
87990A106TNYATenaya Therapeutics, Inc.$55.2M21.4%9,400,290CommonSOLE
75382E109RAPT Therapeutics Inc$50.1M19.5%2,680,621CommonSOLE
62921N105NGMUSDNGM Biopharmaceuticals Inc$47.0M18.2%18,136,735CommonSOLE
68622P109ORICORIC Pharmaceuticals Inc.$27.7M10.7%3,568,181CommonSOLE
86889P109Surrozen, Inc.$5.2M2.01%9,414,795CommonSOLE
28202V108eFFECTOR Therapeutics Inc$3.6M1.39%4,309,329CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.